RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care
Retrieved on:
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Health, Intelligence, Drug utilization review, Pharmacy, Ulcerative colitis, Joint, CEO, Multiple sclerosis, TNF inhibitor, RA, PBM, Plasma protein binding, Rheumatoid arthritis, Multimedia, Arthritis Foundation, Medicine, Woman, Partnership, Twitter, Arthritis, Inflammation, LinkedIn, Therapy, Degenerative disease, Precision medicine, Physician, Autoimmunity, Sickle Cell Anemia, a Molecular Disease, Patient, FDA, Man, Pharmaceutical industry, PrismRA®, Scipher Medicine®, RxParadigm, PRISMRA®, SCIPHER MEDICINE®, RXPARADIGM
PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).
Key Points:
- PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).
- PrismRA tests for patient response and enables them to start more effective FDA-approved therapies from the outset.
- Scipher Medicines health economic analyses suggest that integrating PrismRA into the care pathway for patients with RA improves outcomes while decreasing drug and other medical costs.
- "PrismRA empowers pharmacy benefit managers to guide and optimize drug utilization, which improves patient outcomes and lowers costs.